Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 30INDUSTRY 4NETWORK 1FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Exanthema 1Colonic Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Doxycycline × Clear all
NCT06120140 2026-06-05

COCOON

Janssen Research & Development, LLC

Phase 2 Active not recruiting
305 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02201381 2022-07-18

METRICS

Health Clinics Limited

Phase 3 Withdrawn
BreastCNSGastrointestinalGynecologic

Brain Neoplasms, Breast Neoplasms, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01465802 2019-01-09

ARCHER 1042

Pfizer

Phase 2 Completed
236 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02239731 2018-02-27

Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

Vyne Therapeutics Inc.

Phase 2 Completed
24 enrolled

Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡